Publications

Catherine C Smith, Elisabeth Lasater, Melissa Mccreery, Kimberly Lin, Whitney Stewart, Lauren E Damon, Alexander E Perl, Grace R Jeschke, Mayumi Sugita, Martin Carroll, Scott C. Kogan, Neil Shah. Crenolanib (CP-868,596) Is a Potent and Selective Type I FLT3 Inhibitor That Retains Activity Against AC220 Resistance-Causing FLT3 Kinase Domain Mutants. Blood. 2012. PMID:


Catherine Smith, MD

Catherine C Smith, Michael Brown, Wendy T Parker, Kimberly Lin, Kevin Travers, Susana Wang, Susan Branford, Neil Shah. Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects the Evolution of Polyclonal and Compound BCR-ABL Mutations in Patients Who Relapse On Kinase Inhibitor Therapy. Blood. 2012. PMID:


Catherine Smith, MD

Alexander E Perl, Grace R Jeschke, Catherine C Smith, James K. Mangan, Selina M. Luger, Martin Carroll. Single-Cell Pharmacodynamic Monitoring of Ribosomal Protein S6 Phosphorylation During AC220 Therapy Demonstrates in Vivo FLT3 Inhibition in Circulating Leukemic Blasts and Accurately Detects the Development of AC220 Resistance. Blood. 2012. PMID:


Catherine Smith, MD

Gautam Borthakur, Leslie Popplewell, Michael Boyiadzis, James M. Foran, Uwe Platzbecker, Norbert Vey, Walter B. Roland, Rebecca L. Olin, Azra Raza, Aristotles Giagounidis, Oliver G. Ottmann, Aref Al-Kali, Elias J. Jabbour, Tapan M. Kadia, Guillermo Garcia-Manero, John W. Bauman, Yuehui Wu, Yuan Liu, Dan Schramek, John Z. Zhu, Paul Wissel, Hagop M. Kantarjian. Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease. Blood. 2012. PMID:


Rebecca Olin, MD, MSCE

James L. Rubenstein, Eric D. Hsi, Jeffrey L. Johnson, Sin-Ho Jung, Barbara Grant, Bruce D. Cheson, Lawrence D. Kaplan. BCL6 Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS Lymphoma: Final Report of CALGB 50202 (Alliance). Blood. 2012. PMID:


James Rubenstein, MD, PhD

Willard Cheng, Elisabeth Lasater, Catherine C Smith, Mouanoutoua Mokang, Yun Bao, Neil Shah. Competitive Allele Specific TaqMan® PCR (castPCR™) Technology for Sensitive Detection of AC220-Resistant FLT3 Kinase Domain Mutations in Primary AML Patient Samples. Blood. 2012. PMID:


Catherine Smith, MD

Catherine C Smith, Jason Chin, Elisabeth Lasater, Amy L. Paguirigan, Kimberly Lin, Whitney Stewart, Sara Salerno, Lauren E Damon, Mark J. Levis, Alexander E Perl, Kevin Travers, Andrew Kasarskis, Jerald P. Radich, Neil Shah. Constitutively Activating Mutations At the FLT3 Activation Loop Residue D835 Are Associated with Clinical Resistance to AC220. Blood. 2012. PMID:


Catherine Smith, MD

Greenberg PL, Garcia-Manero G, Moore M, Damon L, Roboz G, Hu K, Yang AS, Franklin J. A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. Leukemia & lymphoma. 2012. PMID: 22906162


Lloyd Damon, MD

Ragupathi L, Najfeld V, Chari A, Petersen B, Jagannath S, Mascarenhas J. A case report of chronic myelogenous leukemia in a patient with multiple myeloma and a review of the literature. Clinical lymphoma, myeloma & leukemia. 2012. PMID: 23168212


Ajai Chari, MD

Engelhardt KR, Shah N, Faizura-Yeop I, Kocacik Uygun DF, Frede N, Muise AM, Shteyer E, Filiz S, Chee R, Elawad M, Hartmann B, Arkwright PD, Dvorak C, Klein C, Puck JM, Grimbacher B, Glocker EO. Clinical outcome in IL-10- and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation. The Journal of allergy and clinical immunology. 2012. PMID: 23158016


Neil Pravin Shah, MD, PhD

Levy JA, Levy Y. HIV infection: what should be considered in approaches for a cure? AIDS (London, England). 2012. PMID: 23060292


Jay Levy, MD

Chien AJ, Rugo HS. Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Breast cancer research and treatment. 2012. PMID: 23143215


Hope Rugo, MD

Chien AJ, Rugo HS. Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Breast cancer research and treatment. 2012. PMID: 23143215


Jo Chien, MD

Magbanua MJ, Sosa EV, Roy R, Eisenbud LE, Scott JH, Olshen A, Pinkel D, Rugo HS, Park JW. Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer research. 2012. PMID: 23135909


John Park, MD

Magbanua MJ, Sosa EV, Roy R, Eisenbud LE, Scott JH, Olshen A, Pinkel D, Rugo HS, Park JW. Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer research. 2012. PMID: 23135909


Hope Rugo, MD

Meyerhardt JA, Sato K, Niedzwiecki D, Ye C, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Wigler DS, Venook A, Fuchs CS. Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. Journal of the National Cancer Institute. 2012. PMID: 23136358


Alan Venook, MD

Van Loon K, Venook AP. Counterpoint: Adjuvant therapy in stage II colon cancer: pain not justified by the gain. Journal of the National Comprehensive Cancer Network : JNCCN. 2012. PMID: 23138166


Alan Venook, MD

Van Loon K, Venook AP. Counterpoint: Adjuvant therapy in stage II colon cancer: pain not justified by the gain. Journal of the National Comprehensive Cancer Network : JNCCN. 2012. PMID: 23138166


Katherine Van Loon, MD, MPH

Keck S, Glencer AC, Rugo HS. Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer. Future oncology (London, England). 2012. PMID: 23148612


Hope Rugo, MD

Amin DN, Sergina N, Lim L, Goga A, Moasser MM. HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. The Biochemical journal. 2012. PMID: 22853430


Mark Moasser, MD